Tocilizumab biosimilar - Oncobiologics

Drug Profile

Tocilizumab biosimilar - Oncobiologics

Alternative Names: ONS-3030

Latest Information Update: 05 Oct 2015

Price : $50

At a glance

  • Originator Oncobiologics
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ankylosing spondylitis; Chronic lymphocytic leukaemia; Crohn's disease; Dermatomyositis; Giant lymph node hyperplasia; Juvenile rheumatoid arthritis; Multiple myeloma; Pancreatic cancer; Polymyositis; Rheumatoid arthritis

Most Recent Events

  • 01 Oct 2015 Preclinical trials in Polymyositis, Pancreatic cancer, Multiple myeloma, Giant lymph node hyperplasia, Juvenile rheumatoid arthritis, Crohn's disease, Dermatomyositis, Chronic lymphocytic leukaemia, Ankylosing spondylitis and Rheumatoid arthritis in USA (IV) before October 2015
  • 01 Oct 2015 Preclinical trials in Juvenile rheumatoid arthritis in USA (SC) before October 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top